Search Results

Apex Labs Ltd. (APEX or the Company) is pleased to announce the filing of an IND application with the U.S. Food and Drug Administration (FDA) for APEX-002-B01-02, a pioneering pharmacokinetics and driving simulator study of APEX-52 take home microdose psilocybin.

Wellbeing Digital Sciences Inc. will participate in Microdose’s Psychedelic Capital: September 2022 Conference to be held virtually on September 29, 2022 at 1:30 p.m. ET.

Eyenovia, Inc., a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, showcased the Microdose Array Print Technology at CES 2023 in Las Vegas, Nevada, from Jan. 5-8.

MindBio Therapeutics Corp. is pleased to have started pre-screening for participant entry into Phase 2 LSD-Microdosing clinical trials.

MindBio Therapeutics Corp. demonstrates how 1 million microdoses of LSD could potentially benefit tens of thousands of patients with Depression.

Apex Labs Ltd. (APEX or the Company) is pleased to announce the completion of the first-ever take home microdose psilocybin clinical trial, meeting all endpoints over a two month period with no adverse events.

Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that it has completed production of psilocybin microdose capsules in collaboration with the Toronto Institute of Pharmaceutical Technology (TIPT®).